Innate Pharma S.A. | Mutual Funds
Mutual Funds that own Innate Pharma S.A.
Oppenheimer Global Opportunities Fund
1,000,000
1.74%
0
0.06%
03/31/2018
Royance Sélection Internationale
380,577
0.66%
0
9.43%
05/31/2018
Vanguard International Explorer Fund
341,522
0.59%
0
0.04%
06/30/2018
HSBC Small Cap France
335,096
0.57%
-7,580
0.57%
12/29/2017
Wellington Mgmt. Port (Dublin) Plc - Global Health Care Eq.
322,593
0.56%
37,593
0.08%
12/31/2017
300,000
0.52%
0
0.24%
03/31/2018
Government Pension Fund - Global (The)
249,139
0.43%
-249,174
0%
12/31/2017
iShares MSCI EAFE Small Cap ETF
195,531
0.34%
0
0.01%
09/06/2018
Aviva France Opportunités
165,338
0.28%
0
0.48%
08/31/2018
Etoile Santé Europe
122,042
0.21%
0
0.34%
01/31/2018
| Address |
117, Avenue de Luminy
Marseille Provence-Alpes-Cote-dAzur 13009
France
|
|
Employees
|
- |
| Website |
http://www.innate-pharma.com/en |
| Updated |
07/08/2019 |
| Innate Pharma SA is a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. |
